- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03537547
Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Major Depressive Disorder is a chronic psychiatric illness that leads to devastating consequences at the individual and societal levels. Today, the choice of treatment continues to be largely based on subjective factors, primarily the clinician and/or patient's preferences, as well as the individual's history of response to treatment, often tainted by recall bias. Psychiatric medication decisions are even more arbitrary when the subject in question has not had past treatment trials. This often leads to a trial and error process and an increasingly resistant disease with each failed trial. Early implementation of an objective tool designed for tailoring medication choice to an individual may prove highly beneficial in decreasing illness chronicity, individual suffering, and economic burden.
GeneSight Psychotropic test is a pharmacogenomic decision support tool, developed to help clinicians make informed, evidence-based decisions about proper drug selection. Therefore, we propose conducting a randomized, double blind, controlled trial to evaluate the impact of the GeneSight Psychotropic test to guide treatment decisions in patients with treatment-naïve (never having taken medication for depression) Major Depressive Disorder.
This study will involve 6 visits over about 24 weeks where participants will be randomized to have their study clinician have access to their pharmacogenetic report in order to make treatment decisions, or to not have access to their report for the first 12 weeks. At Visit 5, Week 12, all participants will receive a copy of their pharmacogenetics report and all clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults 18-65 years of age
- Treatment-naïve major depressive disorder meeting Diagnostic and Statistical Manual 4th Edition (DSM-IV) criteria, without psychosis
- Total baseline score on the Quick Inventory Of Depressive Symptomatology Clinician-rated (QIDS-C16) and the Quick Inventory Of Depressive Symptomatology Self-Report (QIDS-SR16) rating scale ≥11
- Good command of the English language
Exclusion Criteria:
- Patients with a current diagnosis of schizophrenia
- Patients with a current diagnosis of schizoaffective disorder
- Patients with a current diagnosis of bipolar disorder (any type)
- Currently meeting DSM-IV criteria for significant substance use disorder (exception: nicotine use disorder)
- A diagnosis of personality disorder that may interfere with the patient's ability to improve on pharmacologic treatment, as determined by study investigator
- Patients currently receiving electroconvulsive therapy(ECT), deep brain stimulation (DBS) or transcranial magnetic stimulation (TMS) treatment
- History of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic or euthyroid for 6 months
- Significant unstable medical condition; life threatening disease; hepatic insufficiency; liver transplant recipient; cirrhosis of the liver; need for therapies that may obscure the results of treatment and/or of the study; malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications
- History of gastric bypass surgery
- Acute suicidal intention and/or in need of immediate hospitalization as judged by the investigator
- Active psychotic symptoms
- Currently in an inpatient facility
- History of prior pharmacogenomic testing
- Currently pregnant or lactating
- Inability to provide informed consent
- Any other factor that in the investigators' judgment may affect patient safety or compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: GeneSight Psychotropic test
Participants randomized to have their study clinician have access to their pharmacogenetic report (provided through the GeneSight Psychotropic tool) in order to make treatment decisions for the first 12 weeks.
At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will continue to be able to use the results to guide treatment options for an additional 12 weeks.
|
GeneSight Psychotropic test, developed by AssureRx Health, is a genetic test that analyses pre-selected pharmacokinetics and pharmacodynamics genes and results in a composite phenotype and interpretive report, addressing both safety and efficacy of psychiatric medications.
Other Names:
Participant is treated with medications included in the GeneSight Psychotropic product.
|
ACTIVE_COMPARATOR: Treatment As Usual
Participants randomized to treatment as usual will receive treatment from study clinicians who do not have access to the participant's report for the first 12 weeks.
At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.
|
Participant is treated with medications included in the GeneSight Psychotropic product.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Rating Scale for Depression change score- Week 8
Time Frame: Baseline to Week 8
|
17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity.
Total range of the Hamilton Rating Scale for Depression is 0 to 52, with a greater score being an indication of more severe depressive symptoms.
|
Baseline to Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Rating Scale for Depression change score- Week 4
Time Frame: Baseline to end of week 4
|
17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity.
Total range of the Hamilton Rating Scale for Depression is 0 to 52, with a greater score being an indication of more severe depressive symptoms.
|
Baseline to end of week 4
|
Hamilton Rating Scale for Depression change score- Week 12
Time Frame: Baseline to end of week 12
|
17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity.
17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity.
Total range of the Hamilton Rating Scale for Depression is 0 to 52, with a greater score being an indication of more severe depressive symptoms.
|
Baseline to end of week 12
|
Hamilton Rating Scale for Depression change score- Week 24
Time Frame: Baseline to end of week 24
|
17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity.
17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity.
Total range of the Hamilton Rating Scale for Depression is 0 to 52, with a greater score being an indication of more severe depressive symptoms.
|
Baseline to end of week 24
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201609109
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on GeneSight Psychotropic test
-
Assurex Health Inc.University of MichiganCompletedMajor Depressive Disorder (MDD)United States
-
St. Joseph's Healthcare HamiltonCentre for Addiction and Mental Health; Assurex Health Inc.; Genome Canada; Programs... and other collaboratorsCompletedSchizophrenia | Schizoaffective DisorderCanada
-
Assurex Health Inc.Centre for Addiction and Mental Health; Genome Canada; Programs for Assessment... and other collaboratorsCompletedDepressive Disorder | Depression | Depressive Disorder, MajorCanada
-
Massachusetts General HospitalPatient-Centered Outcomes Research Institute; Duke University; Montefiore Medical... and other collaboratorsCompletedMajor Depressive DisorderUnited States
-
Mayo ClinicAssurex Health HomeCompletedDepressionUnited States
-
Mayo ClinicCompleted
-
Mayo ClinicCompletedDepression | Mood Disorder | BipolarUnited States
-
VA Office of Research and DevelopmentCompleted
-
Azienda Socio Sanitaria Territoriale degli Spedali...IRCCS Istituto Centro San Giovanni di Dio- FatebenefratelliRecruitingMajor Depressive DisorderItaly
-
Pure GreenUnknownPain | Osteoarthritis, KneeUnited States